Drugs / QLS1410
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07358858 | Jan → Feb 2026 overdue | hypertensive disorder | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07152444 | Sep 2025 → May 2026 overdue | essential hypertension | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07550465 | Jun 2026 → Apr 2027 expected | primary aldosteronism | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07489612 | Apr → Dec 2026 expected | hypertensive disorder | Qilu Pharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS1410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07550465 ↗ |
| Action | Inhibit | “QLS1410 (CYP11B2 inhibitor)” NCT07152444 ↗ |
| Route | Oral | “QLS1410 tablet administered orally, once daily (QD).” NCT07489612 ↗ |
| Target | CYP11B2 | “QLS1410 (CYP11B2 inhibitor)” NCT07152444 ↗ |